FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2030590964> ?p ?o ?g. }

• W2030590964 abstract "Activation of coagulation appears to play a role in tumor progression. This report describes the preliminary results of a phase II study using docetaxel plus enoxaparin in 15 patients with stage IV non-small cell lung cancer (NSCLC). Time to progression was the primary endpoint. Several surrogate markers of coagulation and angiogenesis were evaluated. Enoxaparin was administered at a daily dose of 1 mg/kg (subcutaneously). The initial dose of docetaxel was 100 mg/m2, given as a 60 min infusion every 21 days with prophylactic dexamethasone. Eight patients achieved an objective response (53%) and four had stable disease, with a median duration of 3.5 months. The median time to progression was 5 months (range, 2 to >15 months). The median survival was 11 months. The most frequent toxicities were neutropenia and asthenia. No significant bleeding or thrombotic events were observed. Eleven patients had elevated D-dimer plasma levels prior to therapy, and seven of these patients with a response or stable disease had a significant decline of the D-dimer during therapy. There were no consistent changes of the plasma levels of the angiogenic factors, except for transforming growth factor-beta-1 (TGF-beta1). The median baseline level of TGF-beta1 prior to therapy was 34,867 pg/ml. Twelve out of 13 patients who achieved a response or stable disease had a significant reduction of the TGF-beta1 levels during therapy. Enoxaparin in combination with chemotherapy was safe and well tolerated in patients with advanced NSCLC. This preliminary data suggests that enoxaparin may prolong the time to progression, and therefore justify the continuation of this trial." @default.
• W2030590964 created "2016-06-24" @default.
• W2030590964 creator A5008626205 @default.
• W2030590964 creator A5015449185 @default.
• W2030590964 creator A5017045908 @default.
• W2030590964 creator A5043419444 @default.
• W2030590964 creator A5059919595 @default.
• W2030590964 date "2003-11-01" @default.
• W2030590964 modified "2023-09-27" @default.
• W2030590964 title "Phase II study of docetaxel plus enoxaparin in chemotherapy-naive patients with metastatic non-small cell lung cancer: preliminary results" @default.
• W2030590964 cites W1524114372 @default.
• W2030590964 cites W1565561072 @default.
• W2030590964 cites W1654829204 @default.
• W2030590964 cites W1789222663 @default.
• W2030590964 cites W1822598714 @default.
• W2030590964 cites W1826360242 @default.
• W2030590964 cites W1839238860 @default.
• W2030590964 cites W1954910358 @default.
• W2030590964 cites W1965288495 @default.
• W2030590964 cites W1965779501 @default.
• W2030590964 cites W1974571648 @default.
• W2030590964 cites W1987199100 @default.
• W2030590964 cites W1993312145 @default.
• W2030590964 cites W1996544895 @default.
• W2030590964 cites W1997001753 @default.
• W2030590964 cites W1997234690 @default.
• W2030590964 cites W2014844181 @default.
• W2030590964 cites W2022131864 @default.
• W2030590964 cites W2024955180 @default.
• W2030590964 cites W2027712708 @default.
• W2030590964 cites W2028915127 @default.
• W2030590964 cites W2029409133 @default.
• W2030590964 cites W2031100117 @default.
• W2030590964 cites W2037139573 @default.
• W2030590964 cites W2043374008 @default.
• W2030590964 cites W2046778136 @default.
• W2030590964 cites W2055942941 @default.
• W2030590964 cites W2062262181 @default.
• W2030590964 cites W2068234939 @default.
• W2030590964 cites W2075583024 @default.
• W2030590964 cites W2088660189 @default.
• W2030590964 cites W2095207165 @default.
• W2030590964 cites W2096497763 @default.
• W2030590964 cites W2138368121 @default.
• W2030590964 cites W2167805334 @default.
• W2030590964 cites W2262127979 @default.
• W2030590964 cites W2295193592 @default.
• W2030590964 cites W2313628137 @default.
• W2030590964 cites W2328710175 @default.
• W2030590964 cites W4230178784 @default.
• W2030590964 cites W4299883346 @default.
• W2030590964 doi "https://doi.org/10.1016/s0169-5002(03)00354-4" @default.
• W2030590964 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14568692" @default.
• W2030590964 hasPublicationYear "2003" @default.
• W2030590964 type Work @default.
• W2030590964 sameAs 2030590964 @default.
• W2030590964 citedByCount "19" @default.
• W2030590964 countsByYear W20305909642012 @default.
• W2030590964 countsByYear W20305909642014 @default.
• W2030590964 countsByYear W20305909642015 @default.
• W2030590964 countsByYear W20305909642017 @default.
• W2030590964 crossrefType "journal-article" @default.
• W2030590964 hasAuthorship W2030590964A5008626205 @default.
• W2030590964 hasAuthorship W2030590964A5015449185 @default.
• W2030590964 hasAuthorship W2030590964A5017045908 @default.
• W2030590964 hasAuthorship W2030590964A5043419444 @default.
• W2030590964 hasAuthorship W2030590964A5059919595 @default.
• W2030590964 hasConcept C126322002 @default.
• W2030590964 hasConcept C141071460 @default.
• W2030590964 hasConcept C143998085 @default.
• W2030590964 hasConcept C203092338 @default.
• W2030590964 hasConcept C2776256026 @default.
• W2030590964 hasConcept C2776694085 @default.
• W2030590964 hasConcept C2776907518 @default.
• W2030590964 hasConcept C2777063308 @default.
• W2030590964 hasConcept C2781190966 @default.
• W2030590964 hasConcept C31760486 @default.
• W2030590964 hasConcept C535046627 @default.
• W2030590964 hasConcept C71924100 @default.
• W2030590964 hasConcept C90924648 @default.
• W2030590964 hasConceptScore W2030590964C126322002 @default.
• W2030590964 hasConceptScore W2030590964C141071460 @default.
• W2030590964 hasConceptScore W2030590964C143998085 @default.
• W2030590964 hasConceptScore W2030590964C203092338 @default.
• W2030590964 hasConceptScore W2030590964C2776256026 @default.
• W2030590964 hasConceptScore W2030590964C2776694085 @default.
• W2030590964 hasConceptScore W2030590964C2776907518 @default.
• W2030590964 hasConceptScore W2030590964C2777063308 @default.
• W2030590964 hasConceptScore W2030590964C2781190966 @default.
• W2030590964 hasConceptScore W2030590964C31760486 @default.
• W2030590964 hasConceptScore W2030590964C535046627 @default.
• W2030590964 hasConceptScore W2030590964C71924100 @default.
• W2030590964 hasConceptScore W2030590964C90924648 @default.
• W2030590964 hasLocation W20305909641 @default.
• W2030590964 hasLocation W20305909642 @default.
• W2030590964 hasOpenAccess W2030590964 @default.
• W2030590964 hasPrimaryLocation W20305909641 @default.
• W2030590964 hasRelatedWork W2048508102 @default.
• W2030590964 hasRelatedWork W2083686235 @default.
• W2030590964 hasRelatedWork W2168103287 @default.

• next